Overexpression of FGFR1 promoted a significant increase in growth rate of HME2 tumors upon mammary fat pad engraftment, leading to differential TDM1 treatment initiation times for matched tumor sizes (Fig. 4A). This evidence concerns the gene FGFR1 and neoplasm.